Does Cannabis or CBD Help With Pain?

Cannabis has been legal in Canada since October 2018, which means the shop on the main street sells something that no major pain organisation in the world currently recommends for pain. That is not a contradiction anybody set out to create. It is what happens when a product becomes legal for adults to buy at the same time as the trials testing it keep coming back small, short and unconvincing.

The honest summary is narrower than either side of the argument suggests. Cannabis is not useless for pain — the best evidence says a minority of people get a real, worthwhile improvement, and the guideline panels have stopped pretending otherwise. But it is also nothing like the treatment the retail counter implies. Most of the measurable effect comes from THC, the part that gets you high. CBD on its own, which is what most people asking about this actually want, has almost nothing behind it.

Two different drugs in one plant

Cannabis contains more than a hundred cannabinoids, but only two matter for this conversation.

THC — tetrahydrocannabinol — is the intoxicating one. It is also the one carrying nearly all the measurable pain effect in the trials. Dizziness, sedation, dry mouth and the feeling of being stoned come with it, because they are the same molecule doing the same thing.

CBD — cannabidiol — is not intoxicating. It is the component sold as oils, capsules and creams to people who want the benefit without the high, and it is the component with the weakest evidence for pain in the entire field.

What decides how a product behaves is the ratio between them, not the name on the bottle or whether the label says “full spectrum”. A product described as high-CBD may contain enough THC to be sedating; a “balanced” one has roughly equal amounts of both. When a study reports on cannabis for pain, the first question to ask is which of those it tested, because the answers are genuinely different.

What the trials actually found

The guideline that changed the conversation

The most influential review is a 2021 clinical practice guideline led from McMaster University, which pooled 32 randomised trials covering 5,174 people with chronic pain of every kind — nerve pain, arthritis pain, fibromyalgia, cancer pain. Its panel made a deliberately weak recommendation: offer a trial of non-inhaled medical cannabis to people whose standard care is not managing their pain.

Weak is the operative word, and the numbers behind it are worth seeing plainly. The panel was confident — high-certainty evidence — that cannabis produces a small increase in the number of people getting an important improvement in pain, a small increase for sleep quality, and a very small increase for physical function. It was equally confident that cannabis does not improve emotional functioning, role functioning or social functioning at all.

The panel’s own illustration of the size of the effect is the most useful sentence in the document: a roughly 1 in 10 chance of experiencing important pain relief. Nine people in ten get the side effects and not the benefit. For someone whose current treatment is doing nothing, a one-in-ten shot at something worthwhile may be well worth taking. For someone managing reasonably already, it may not be. That is precisely why the recommendation is weak rather than a recommendation against — the arithmetic changes depending on where you are starting from.

Two limits on that guideline matter. It applies only to non-inhaled forms — oils, sprays, capsules — because no eligible trial tested smoking or vaping. And 21 of the 32 trials were industry funded.

Nerve pain

Nerve pain is where cannabis has been studied most, and Cochrane updated its review of it in January 2026. Pooling 21 trials and more than 2,100 adults, cannabis-based medicines for chronic neuropathic pain produced this:

• Pain down by at least 30%: 39% of people on cannabis, against 33% on placebo. Eleven people have to be treated for one extra person to get there.
• Pain down by at least half: 21% against 17%. That takes twenty people treated for one extra success, and the reviewers rated the evidence low quality.
• Nervous system side effects: 61% against 29% on placebo.
• Psychiatric side effects: 17% against 5%.
• Stopped because of side effects: 10% against 5%.

The reviewers concluded that the potential benefits were outweighed by the potential harms — while adding, correctly, that a minority of people do get substantial relief without trouble. Both halves of that sentence are true at once, and which half applies to you is not currently predictable in advance.

Which product, though

The freshest look at that question is an updated systematic review published in Annals of Internal Medicine in early 2026, which sorted 25 trials in 2,303 people by THC-to-CBD ratio rather than by brand or format. Sorting them that way makes the pattern obvious:

• Products with a comparable THC-to-CBD ratio, given as an oromucosal spray, probably reduce pain slightly — about half a point on a ten-point scale.
• THC-dominant products may reduce pain slightly, but the category hides a split: the synthetic cannabinoid nabilone reduced pain by 1.6 points, while dronabinol managed 0.2 and was indistinguishable from placebo.
• Low THC-to-CBD products — the CBD-dominant ones — may not improve outcomes at all. They also may not increase side effects, which is a fair description of a substance that is doing very little in either direction.

Every one of those effects was measured over one to six months. Nobody has run a good trial of what any of this does over the years that chronic pain actually lasts.

The CBD problem

CBD deserves its own section, because it is what most people mean when they ask about this, and because it is where the gap between marketing and evidence is widest.

The cleanest test to date randomised 136 people with hand osteoarthritis or psoriatic arthritis to synthetic CBD or placebo for twelve weeks, on top of whatever they were already taking. The difference in pain after twelve weeks was 0.23 mm on a 100 mm scale, with a p-value of 0.96 — as close to no difference as a trial can produce. Nothing happened to sleep quality, anxiety, depression or pain catastrophising either. Twenty-two percent of the CBD group had a meaningful drop in pain; so did 21% of the placebo group.

This is the trial that people who have found CBD helpful are usually being told about, and it is worth being precise about what it shows. It does not prove CBD does nothing for anyone. It shows that at 20 to 30 mg a day for twelve weeks, in two specific arthritic conditions, it did not beat a placebo — and that placebo, notably, helped one person in five.

Dose is the fairest objection. The CBD doses that unambiguously do something in medicine are enormous: the licensed epilepsy formulation runs from 5 to 20 mg per kilogram per day, which for an average adult is hundreds of milligrams. A retail bottle delivering 15 mg in a dropper is a different order of magnitude. Whether high-dose CBD helps pain is genuinely unknown; whether the dose in the bottle on the shelf does is much closer to answered.

The International Association for the Study of Pain reviewed all of this and declined to endorse cannabinoids for pain, while explicitly refusing to dismiss the experience of people who have found them helpful. That is the most accurate position anyone has managed to state.

Choosing between the three

What it does not do

It does not treat the cause of anything. No cannabinoid slows joint erosion, decompresses a nerve or repairs a disc. Like a TENS machine or a heat pack, it manages a symptom.

The opioid-sparing claim — that cannabis lets people reduce their opioid dose — is the one most often repeated and least well supported. The McMaster panel rated the evidence for it very low certainty, meaning nobody knows. Clinicians may reasonably use cannabis as part of a voluntary opioid taper, but that is a hope resting on weak ground rather than a demonstrated effect.

And it does not improve mood, social life or the ability to fill your role at home or at work. That was high-certainty evidence, and it is the finding most at odds with how cannabis is marketed to people in pain.

Getting it legally in Canada

There are two doors, and most people do not realise they are different.

The retail door is the one everyone knows: any adult can buy cannabis, including CBD oils, from a provincially licensed store or its website, no authorisation needed. Everything sold there is tested and labelled under federal rules. Note that CBD is a controlled substance under the Cannabis Act — legal CBD comes from cannabis retailers, not from health food shops, gas stations or American websites, whatever those are selling.

The medical door runs through a health care practitioner, who provides a medical document rather than a prescription. You send it to a federally licensed seller and order directly, or register with Health Canada to grow a limited amount yourself. The practical differences are real: access to clinical guidance, product consistency, tax treatment, and eligibility for insurance.

The wording matters more than it sounds. With two exceptions, cannabis products in Canada are authorised, not prescribed — they have no Drug Identification Number, so a pharmacist cannot dispense them and most drug plans will not process them. The exceptions are nabiximols (Sativex), the oromucosal balanced spray used in much of the trial evidence, and nabilone (Cesamet), a synthetic THC capsule. Both hold DINs and can be prescribed normally; you can look either up in Health Canada’s Drug Product Database. Given that nabilone was the one THC product to reduce pain by a clinically meaningful amount in the 2026 review, it is a reasonable thing to raise with a doctor before going shopping.

Canada’s simplified guideline for prescribing medical cannabinoids in primary care, written for family physicians, takes a narrower line than the international one: it suggests limiting cannabinoids to a short list of situations — neuropathic pain, palliative pain, chemotherapy nausea, and spasticity in MS or spinal cord injury — and trying licensed products like nabilone or nabiximols first. If your doctor seems cautious, this is likely why, and it is a defensible position rather than an obstructive one.

What it costs

No provincial drug plan covers cannabis for pain. Some private extended health plans do, usually requiring a medical document, so ask before you buy rather than after.

Two exceptions are worth knowing. Veterans Affairs Canada reimburses cannabis for medical purposes for eligible veterans up to 3 grams a day, at a rate that Budget 2025 reduced from $8.50 to $6.00 per gram. And cannabis bought with a medical document from a licensed seller is an eligible medical expense for the medical expense tax credit — keep the receipts, since retail purchases without a medical document do not qualify. Medical cannabis still carries the same excise tax as recreational cannabis, a point Arthritis Society Canada has campaigned on for years without success.

If you decide to try it

The McMaster guideline includes a starting protocol, and it is deliberately unglamorous: begin with a low-dose, non-inhaled CBD product — roughly 5 mg twice a day — increasing by about 10 mg every two or three days to a maximum of 40 mg daily. If that achieves nothing, THC is added in 1 to 2.5 mg steps every few days. Do this with the practitioner who authorised it, not alone.

Three practical points that catch people out:

• Swallowed cannabis is slow. Only 13% to 19% of an oral dose reaches the bloodstream, and it can take four hours to peak. The commonest mistake — and the commonest route to a frightening evening — is taking a second dose because the first has not worked yet.
• Start in the evening. The first dose that does anything is likely to make you dizzy or drowsy. Meet that at home with nothing to do, not before driving to an appointment.
• Change one thing at a time. Give each step a fortnight and write down pain, sleep and side effects. Cannabis that helps sleep and does nothing for pain is a common and perfectly reasonable outcome — but you will not spot it if you change dose, product and format in the same week.

Who should be more careful

Age is the risk factor this site’s readers are most likely to have. Ontario emergency departments recorded 2,322 visits for cannabis poisoning in people over 65 across eight years, and the rate roughly quadrupled between the years before legalisation and the years after edibles went on sale — from 5.8 to 21.1 per 100,000. Older bodies clear THC more slowly, take more other medicines, and fall harder. None of that makes cannabis off limits after 65; all of it argues for a smaller starting dose than the label suggests.

Beyond that:

• A history of psychosis, schizophrenia or bipolar disorder, personal or in the family. THC is the problem here, not CBD.
• Heart disease. THC raises heart rate and can drop blood pressure on standing.
• Pregnancy or breastfeeding. The guidance is to stop, not to reduce.
• Driving. Canada’s impaired driving law sets a criminal threshold at 2 nanograms of THC per millilitre of blood and a more serious offence at 5, with a minimum $1,000 fine. A medical document is not a defence, and THC lingers far longer than the feeling of being affected.
• A history of problem substance use. Regular cannabis use can become a dependence of its own, and daily heavy use has been linked to worsening rather than improving pain.

Buying something that is what it says

This is the one area where Canadian buyers are genuinely better off than most. Products from a licensed Canadian retailer are tested, and the cannabinoid content printed on the package is the content in the bottle.

Grey-market and imported hemp CBD is a different market. An analysis of 80 unregulated CBD oils found 46% were outside a generous ±10% tolerance of their label claim — most of them containing more than advertised, some containing barely a third of it. If you cannot tell what is in a bottle, you cannot tell whether a fair trial has failed or whether you have been rubbing in an expensive carrier oil.

The same logic applies to topical CBD creams, which occupy a large and profitable corner of the pharmacy shelf on evidence that has never amounted to much. If a cream helps, it is worth asking what the massage and the menthol are contributing before crediting the cannabinoid.

The most defensible thing anyone can say about cannabis for pain is that it works well for a minority, modestly for some, and not at all for most — and that nobody can yet tell you in advance which group you are in.

So is it worth trying?

If standard care is not managing your pain, a supervised trial of a non-inhaled, balanced or low-THC product is a reasonable thing to do. That is roughly what the international guideline says, and the reasoning is sound: the potential benefit is small but real, the serious risks are low, and you will know within a few weeks. Ask specifically about nabilone or nabiximols first, since those are the products with both the better evidence and the ability to be prescribed and covered.

If what you are considering is a CBD oil from a shop, on the strength of what a neighbour told you, the expected value is close to zero and the cost is not. Spend the money on something with better odds — the supplement aisle has a similar problem, but a physiotherapy assessment or a pair of shoes that fit does not.

Either way, it belongs alongside the things that keep a painful day bearable rather than instead of them. Living with chronic pain in Canada covers the wider ground, our free printable plans cover the day-to-day, and Pain BC runs free programs across the country for people building the rest of the plan.